Vor Bio (Nasdaq: VOR) has announced positive data from its ongoing Phase I/II VBP101 study evaluating the combination of trem-cel and Mylotarg (gemtuzumab ozogamicin) in people with relapsed or ...

Vor Bio日前公布其在研干细胞疗法tremtelectogeneempogeditemcel（trem-cel）与CD33靶向抗体偶联药物（ADC）Mylotarg联用，治疗复发/难治性 ...

Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed ...

The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. The full text of the ...

Mylotarg, the first ADC approved by the FDA, is known generically as gemtuzumab ozogamicin. Early ADC linkers were very simple, such as organic chains with acid-labile hydrazone groups.

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging ...

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody ...

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with signif ...